- Home
- HYI vs DCTH Comparison
HYI vs DCTH Comparison
Compare HYI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- DCTH
- Stock Information
- Founded
- HYI 2010
- DCTH 1988
- Country
- HYI United States
- DCTH United States
- Employees
- HYI N/A
- DCTH N/A
- Industry
- HYI Investment Managers
- DCTH Medical/Dental Instruments
- Sector
- HYI Finance
- DCTH Health Care
- Exchange
- HYI Nasdaq
- DCTH Nasdaq
- Market Cap
- HYI 279.2M
- DCTH 305.2M
- IPO Year
- HYI N/A
- DCTH N/A
- Fundamental
- Price
- HYI $12.14
- DCTH $9.85
- Analyst Decision
- HYI
- DCTH Strong Buy
- Analyst Count
- HYI 0
- DCTH 4
- Target Price
- HYI N/A
- DCTH $21.50
- AVG Volume (30 Days)
- HYI 50.6K
- DCTH 436.4K
- Earning Date
- HYI 01-01-0001
- DCTH 11-08-2024
- Dividend Yield
- HYI 9.59%
- DCTH N/A
- EPS Growth
- HYI N/A
- DCTH N/A
- EPS
- HYI N/A
- DCTH N/A
- Revenue
- HYI N/A
- DCTH $22,644,000.00
- Revenue This Year
- HYI N/A
- DCTH $1,562.76
- Revenue Next Year
- HYI N/A
- DCTH $117.72
- P/E Ratio
- HYI N/A
- DCTH N/A
- Revenue Growth
- HYI N/A
- DCTH 945.91
- 52 Week Low
- HYI $10.99
- DCTH $2.60
- 52 Week High
- HYI $12.24
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- HYI 49.92
- DCTH 48.26
- Support Level
- HYI $11.94
- DCTH $9.50
- Resistance Level
- HYI $12.22
- DCTH $10.04
- Average True Range (ATR)
- HYI 0.14
- DCTH 0.65
- MACD
- HYI -0.00
- DCTH -0.12
- Stochastic Oscillator
- HYI 52.63
- DCTH 24.44
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.